6.84

2.24% 0.15

After Hours: 6.75 -0.09 -1.32%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $6.84, with a volume of 1.03M. It is up +2.24% in the last 24 hours and down -17.79% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Previous Close:

$6.69

Open:

$6.65

24h Volume:

1.03M

Relative Volume:

0.97

Market Cap:

$414.44M

Revenue:

$217.11M

Net Income/Loss:

$-651.19M

P/E Ratio:

-0.5266

EPS:

-12.99

Net Cash Flow:

$-387.26M

1W Performance:

-29.56%

1M Performance:

-17.79%

6M Performance:

-38.65%

1Y Performance:

-17.19%

1-Day Range:

$6.60

$7.12

1-Week Range:

$6.3526

$8.27

52-Week Range:

$5.00

$17.58

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

834

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	6.84	405.35M	217.11M	-651.19M	-387.26M	-12.99
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Mar 03, 2026

Ginkgo Bioworks Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:DNA) 2026-03-03 - Seeking Alpha

Mar 03, 2026

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 03, 2026

Mar 02, 2026

Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure - AI Insider

Mar 02, 2026

Ginkgo Bioworks Launches Ginkgo Cloud Lab to Provide Remote Access for Researchers - marketscreener.com

Mar 02, 2026

A Look At Ginkgo Bioworks (DNA) Valuation As It Pivots To Robotics Labs And Biosecurity Divestiture - Sahm

Mar 02, 2026

Mar 01, 2026

DNA SEC FilingsGinkgo Bioworks Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 01, 2026

A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration - Yahoo Finance

Mar 01, 2026

Feb 28, 2026

DNABW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026

Ginkgo Bioworks Q4 Earnings Call Highlights - MarketBeat

Feb 28, 2026

Feb 27, 2026

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of Its Non-Core Biosecurity Business - 富途牛牛

Feb 27, 2026